GE LIFE SCIENCES
Acquired by
DANAHER
GE LIFE SCIENCES acquired by DANAHER
Target
GE LIFE SCIENCES
Acquirer
DANAHER
Context
Danaher has finalized an agreement to acquire GE Biopharma in a transformational all-cash transaction, an operation designed to fundamentally redefine the landscape of the global bioprocessing market. The strategic rationale for this transaction centers on a "Bioprocessing-Powerhouse" play, merging the target's industry-leading technical operational depth in chromatography and cell culture with the group’s established life sciences platform and the power of the Danaher Business System. This structural alignment provides the organization with the scientific talent and technological hardware—specifically across upstream and downstream workflows—required to address the surging global demand for biologic drug development.
GE LIFE SCIENCES, which reported an EBITDA margin of LOGIN in 2019, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the 10.6x average currently observed in the Industry & Manufacturing sector.
Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.
-> Deep-dive in Industry & Manufacturing market trends
Target
GE Biopharma is a USA company specialized in Bioprocessing & Cell Analysis. They have built a distinct space in the healthcare market as the primary provider of the "industrial plumbing" required for the discovery and manufacturing of biologic drugs. Instead of just selling laboratory equipment, they thrive on a philosophy of technical operational depth, providing the essential chromatography hardware, cell culture media, and single-use technologies that allow pharmaceutical companies to scale their innovations. What makes them a go-to partner is their integrated software and consumables model, which ensures that 75% of their revenue is recurring. Their roadmap is centered on enabling the proliferation of complex cell and gene therapies through advanced upstream and downstream processing solutions.
Ent. Value
LOGIN
Equity Value
LOGIN
Multiples Analysis
EV / Revenue
LOGIN
EV / EBITDA
LOGIN
EV / EBIT
LOGIN
Historical Financials (EUR)
Other operations with GE LIFE SCIENCES
mynth data is contributed by M&A / PE professionals and systematically cross-verified against private deal documents and official releases. All source materials are destroyed post-validation to guarantee data anonymity and compliance.